EUVIMEDEUVIMED entdecken
Crossref

Embracing Bayesian Methods in Clinical Trials

J Jack Lee, Frank E Harrell, Lisa M LaVange, David J Spiegelhalter

JAMA · 19.05.2026 · 335 (19) · 1664

DOI: 10.1001/jama.2026.4179 ↗

Kurz gefasst

Fachartikel in der Zeitschrift JAMA, erschienen am 19.05.2026. Verfasst von J Jack Lee und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biostatistics, University of Texas MD Anderson Cancer Center, Houston. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 8 Literaturangaben. Gefördert von: NCI NIH HHS.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

This Perspective discusses the importance of the US Food and Drug Administration’s draft guidance on the use of bayesian methods in clinical trials because it underscores its commitment to modernizing clinical research.

Autor:innen und Institutionen

  • Department of Biostatistics, University of Texas MD Anderson Cancer Center, Houston.
  • Department of Biostatistics, Vanderbilt University, Nashville, Tennessee.
  • Department of Biostatistics, University of North Carolina at Chapel Hill.
  • Statistical Laboratory, Centre for Mathematical Sciences, Cambridge, United Kingdom.

Förderung

  • NCI NIH HHS

Zitieren

APA

Lee, J. J., Harrell, F. E., LaVange, L. M., & Spiegelhalter, D. J. (2026). Embracing Bayesian Methods in Clinical Trials. JAMA, 335(19), 1664. https://doi.org/10.1001/jama.2026.4179

Vancouver

Lee JJ, Harrell FE, LaVange LM, Spiegelhalter DJ. Embracing Bayesian Methods in Clinical Trials. JAMA. 2026;335(19):1664. doi:10.1001/jama.2026.4179

BibTeX
@article{Lee2026,
  author = {Lee, J Jack and Harrell, Frank E and LaVange, Lisa M and Spiegelhalter, David J},
  title = {Embracing Bayesian Methods in Clinical Trials},
  journal = {JAMA},
  year = {2026},
  volume = {335},
  number = {19},
  pages = {1664},
  doi = {10.1001/jama.2026.4179}
}
Kostenlos starten →